Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | BECN1 | Q14457 | 7/20 | 0.45 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13287934 | 0.95 | IL23R (0.52) | IL23RBCL2L1BADBECN1OPRL1 | |
| SCHEMBL12082795 | 0.84 | IL23R (0.52) | IL23RTSLPF12 | |
| SCHEMBL13287941 | 0.79 | SSTR2 (0.50) | IL23RBCL2L1BAD | |
| SCHEMBL13113566 | 0.78 | SSTR2 (0.50) | IL23RBCL2L1BAD | |
| SCHEMBL13659868 | 0.78 | IL23R (0.48) | IL23R | |
| SCHEMBL13659873 | 0.77 | IL23R (0.45) | IL23RBCL2L1BAD | |
| SCHEMBL12082890 | 0.77 | IL23R (0.50) | IL23ROPRL1 | |
| SCHEMBL10046387 | 0.74 | TFPI (0.47) | IL23ROPRL1 | |
| SCHEMBL31181296 | 0.74 | IL23R (0.48) | IL23ROPRL1 | |
| SCHEMBL23057565 | 0.73 | IL23R (0.51) | IL23ROPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258101-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2012-09-04 | — | — | US | disclosed |
| US-20100256330-A1 | Peptide-based compounds | CUTHBERTSON ALAN | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256330-A1 | Peptide-based compounds | VCAM1, FLT4, KDR | IL23R 295/4885BCL2L1 1836/4885BAD 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.